Cerus Corp
Research Cerus Corp (CERS) on Bullrun: market cap USD 547.96M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCERS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 547.96M
- Financial periodQ2 2026
- RevenueUSD 57.44M
- Net income-USD 2.94M
- Free cash flow-USD 3.53M
- Gross margin51.4%
Valuation Snapshot
latest market cap is USD 547.96M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 233.80M | -USD 15.63M | USD 1.11M | 48.0% | -0.08 | USD 19.96M | USD 96.95M | USD 64.22M |
| FY2024 | USD 201.32M | -USD 20.92M | USD 8.52M | 49.4% | -0.11 | USD 20.27M | USD 98.10M | USD 56.15M |
| FY2023 | USD 186.80M | -USD 37.49M | -USD 47.77M | n/a | -0.21 | USD 11.65M | USD 96.00M | USD 52.65M |
| FY2022 | USD 188.32M | -USD 42.78M | -USD 27.62M | n/a | -0.24 | USD 35.59M | USD 87.96M | USD 67.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 547.96M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 395.81M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 286.08M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 391.39M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 647.59M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.18B | n/a | n/a | n/a |
About Cerus Corp
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cerus Corp's market cap?
Cerus Corp's market capitalization is USD 547.96M.
What does Cerus Corp do?
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.